|Bid||16.71 x 800|
|Ask||16.95 x 1000|
|Day's range||16.69 - 17.18|
|52-week range||5.54 - 26.64|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Those following along with Biohaven Ltd. ( NYSE:BHVN ) will no doubt be intrigued by the recent purchase of shares by...
What happened Shares of Biohaven Ltd. (NYSE: BHVN) were crashing 27.5% lower at 11:50 a.m. ET on Thursday. This big sell-off came after the company provided updates on several programs. The most important news for investors is related to Biohaven's New Drug Application (NDA) filing for troriluzole in treating spinocerebellar ataxia type 3 (SCA3), an ultrarare neurodegenerative disorder.
Then you want to check out this pair of drugmakers with huge catalysts on the way. Before blindly risking any of your own hard-earned money, let's look at the catalysts that could make these two top performers. BridgeBio (NASDAQ: BBIO) is a commercial-stage drugmaker with one drug for sale.